$2.4
+0.02
(+0.84%)▲
Live
2.08%
Downside
Day's Volatility :6.74%
Upside
4.76%
46.67%
Downside
52 Weeks Volatility :76.77%
Upside
56.44%
Period | Century Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -17.36% | 6.5% | 0.0% |
6 Months | -43.6% | 7.1% | 0.0% |
1 Year | -21.97% | 9.8% | 0.0% |
3 Years | -91.84% | 14.2% | -20.2% |
Market Capitalization | 201.1M |
Book Value | $2.75 |
Earnings Per Share (EPS) | -2.22 |
Wall Street Target Price | 12.8 |
Profit Margin | 0.0% |
Operating Margin TTM | -3661.87% |
Return On Assets TTM | -19.33% |
Return On Equity TTM | -58.66% |
Revenue TTM | 1.4M |
Revenue Per Share TTM | 0.02 |
Quarterly Revenue Growth YOY | -50.3% |
Gross Profit TTM | 5.2M |
EBITDA | -111.0M |
Diluted Eps TTM | -2.22 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.87 |
EPS Estimate Next Year | -1.83 |
EPS Estimate Current Quarter | -0.5 |
EPS Estimate Next Quarter | -0.49 |
What analysts predicted
Upside of 433.33%
Sell
Neutral
Buy
Century Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Century Therapeutics Inc | -3.25% | -43.6% | -21.97% | -91.84% | -91.38% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Century Therapeutics Inc | 45.5 | NA | NA | -1.87 | -0.59 | -0.19 | NA | 2.75 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Century Therapeutics Inc | Buy | $201.1M | -91.38% | 45.5 | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Century Therapeutics Inc
Revenue is up for the last 4 quarters, 99.0K → 855.0K (in $), with an average increase of 48.9% per quarter
Netprofit is up for the last 2 quarters, -39.39M → -28.06M (in $), with an average increase of 40.4% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 83.6%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 278.3%
VR Adviser, LLC
FMR Inc
Casdin Capital, LLC
Boxer Capital LLC
BlackRock Inc
Dafna Capital Management LLC
Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.
Organization | Century Therapeutics Inc |
Employees | 152 |
CEO | Dr. Adrienne Farid Ph.D. |
Industry | Non-Energy Minerals |
A Spac I Acquisition Corp
$2.40
+0.84%
Keyarch Acquisition Corp
$2.40
+0.84%
Connexa Sports Technologies Inc
$2.40
+0.84%
Us Value Etf
$2.40
+0.84%
First Wave Biopharma Inc
$2.40
+0.84%
Global X Msci Next Emerging
$2.40
+0.84%
Fat Projects Acquisition Corp
$2.40
+0.84%
Capital Link Global Fintech
$2.40
+0.84%
Applied Uv Inc
$2.40
+0.84%